Midamor

Polyuria, Ascites, Hypokalemia + 7 more

Treatment

5 FDA approvals

20 Active Studies for Midamor

What is Midamor

Amiloride

The Generic name of this drug

Treatment Summary

Amiloride is a drug used to prevent the loss of potassium in the body. It works by blocking the reabsorption of sodium in the kidneys, which in turn creates a negative charge that reduces the secretion of potassium and hydrogen ions. Amiloride is usually taken with other diuretics to increase its effectiveness.

Amiloride Hydrochloride

is the brand name

image of different drug pills on a surface

Midamor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Amiloride Hydrochloride

Amiloride

1986

23

Approved as Treatment by the FDA

Amiloride, otherwise called Amiloride Hydrochloride, is approved by the FDA for 5 uses like Congestive Heart Failure (CHF) and Hypokalemia .

Congestive Heart Failure (CHF)

Used in combination with other therapies

Hypokalemia

Congestive Heart Failure

Used in combination with other therapies

kaliuretic diuretics

Hypertensive disease

Effectiveness

How Midamor Affects Patients

Amiloride is a medication used to treat high blood pressure and congestive heart failure. It is an antihypertensive, potassium-sparing diuretic, meaning it helps the body get rid of extra fluids while also helping to keep potassium levels in the blood normal. It is often taken together with other diuretics. High levels of potassium in the blood (hyperkalemia) can occur when taking amiloride, especially if it is combined with ACE inhibitors or spironolactone. People taking this drug should avoid using salt replacements that contain potassium.

How Midamor works in the body

Amiloride works by preventing sodium from being reabsorbed in the kidneys. This causes sodium and water to be excreted from the body, but it does not reduce potassium levels. Amiloride does this by blocking sodium channels in the distal convoluted tubules and collecting ducts. This reduces the negative charge in the tubular lumen, which stops potassium and hydrogen from being secreted. Amiloride does not need aldosterone to work.

When to interrupt dosage

The proposed dosage of Midamor is contingent upon the diagnosed state, including Metabolic Alkalosis, Bartter's syndrome and Congestive Heart Failure. The measure of dosage is subject to the method of delivery (e.g. Oral or Tablet) enumerated in the table underneath.

Condition

Dosage

Administration

Congestive Heart Failure

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Hypertensive disease

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Ascites

, 5.0 mg

, Tablet, Oral, Tablet - Oral

lithium

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Bartter Syndrome

, 5.0 mg

, Tablet, Oral, Tablet - Oral

kaliuretic diuretics

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Nephrolithiasis

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Hypokalemia

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Polyuria

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Metabolic Alkalosis

, 5.0 mg

, Tablet, Oral, Tablet - Oral

Warnings

Midamor possesses four contraindications and should not be consumed in cases of the conditions identified in the table below.

Midamor Contraindications

Condition

Risk Level

Notes

Renal Insufficiency

Do Not Combine

Hyperkalemia

Do Not Combine

potassium supplementation

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Midamor.

Common Midamor Drug Interactions

Drug Name

Risk Level

Description

Cisplatin

Major

The serum concentration of Cisplatin can be increased when it is combined with Amiloride.

Clofarabine

Major

The serum concentration of Clofarabine can be increased when it is combined with Amiloride.

Cyclosporine

Major

The risk or severity of hyperkalemia can be increased when Amiloride is combined with Cyclosporine.

Dalfampridine

Major

The serum concentration of Dalfampridine can be increased when it is combined with Amiloride.

Gentamicin

Major

The serum concentration of Gentamicin can be increased when it is combined with Amiloride.

Midamor Toxicity & Overdose Risk

Taking too much amiloride hydrochloride can be dangerous, as the lethal dose in mice is 56 mg/kg and 36 to 85 mg/kg in rats. Signs of overdose include dehydration and an imbalance of electrolytes in the body.

Midamor Novel Uses: Which Conditions Have a Clinical Trial Featuring Midamor?

Presently, 53 active trials are being conducted to assess the utility of Midamor in treating Hypokalemia, Bartter's Syndrome and Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Hypokalemia

0 Actively Recruiting

Congestive Heart Failure

11 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Hypertensive disease

41 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2

Nephrolithiasis

0 Actively Recruiting

kaliuretic diuretics

0 Actively Recruiting

Ascites

2 Actively Recruiting

Phase 2, Not Applicable

Polyuria

0 Actively Recruiting

Metabolic Alkalosis

0 Actively Recruiting

Bartter Syndrome

0 Actively Recruiting

lithium

0 Actively Recruiting

Midamor Reviews: What are patients saying about Midamor?

3.3

Patient Review

11/4/2015

Midamor for High Blood Pressure

I had a really bad reaction to this medication after consuming alcohol. I was vomiting for hours and ended up in the ER because I couldn't even drink water. They did an endoscopy and found that my throat had closed up. I'm now worried about the long-term side effects of this drug, as they mimic my existing eye conditions.

2.3

Patient Review

9/15/2012

Midamor for High Blood Pressure

I've been urinating frequently, and my muscles have become weak and uncoordinated. This product has not alleviated these issues at all.

Patient Q&A Section about midamor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of diuretic is Midamor?

"Midamor is a water pill that helps prevent your body from absorbing too much salt and keeps your potassium levels from getting too low. It's used to treat or prevent hypokalemia (low potassium levels in the blood) in people with high blood pressure or congestive heart failure."

Answered by AI

Is Midamor a loop diuretic?

"MIDAMOR (amiloride) has been shown to decrease the enhanced urinary excretion of magnesium when used with a thiazide or loop diuretic. MIDAMOR (amiloride) also has potassium-conserving activity in patients receiving kaliuretic-diuretic agents."

Answered by AI

Does Midamor lower potassium?

"Amiloride may cause your body to retain potassium. This is especially likely if you have diabetes, take other diuretics, take medications that can increase potassium in the blood, or if you're over 65."

Answered by AI

What is Midamor used for?

"Amiloride is a medication used to help treat heart conditions like high blood pressure, heart failure, or fluid retention. It is often used in combination with other medications like diuretics and thiazide diuretics. Amiloride can also help to prevent low blood potassium levels that can be caused by other medications."

Answered by AI

Clinical Trials for Midamor

Image of Caridad Center, Inc. in Boynton Beach, United States.

CHW Nutrition Support for Type 2 Diabetes

18+
All Sexes
Boynton Beach, FL

This study tests whether adding CHW support to usual nutrition care helps adults with type 2 diabetes, hypertension, or chronic kidney disease manage their diet and health. At Caridad Center, a free clinic in Palm Beach County, Florida, usual care includes medical nutrition therapy from a registered dietitian and medically tailored groceries. Many patients find it hard to keep up dietary changes because of limited nutrition knowledge, cooking skills, food costs, and cultural fit. Two hundred adults will be randomly assigned to usual care or usual care plus INTEGRATE-CHW, a 12-week program of six sessions with a trained CHW. In each session the participant selects one or two goals from the dietitian's plan and builds an action plan with the CHW. The dietitian remains responsible for the nutrition plan. The study will compare nutrition self-efficacy, nutrition literacy, diet quality, food security, and clinical measures between groups at baseline and Week 12. It will also evaluate how well the program fits into routine clinic care.

Waitlist Available
Has No Placebo

Caridad Center, Inc.

Janet Diaz Martinez

Image of Satellite Healthcare - Daly City in San Francisco, United States.

Blood Pressure Management for Kidney Failure

18+
All Sexes
San Francisco, CA

The GOAL-BP pilot study will help determine whether a study comparing two blood pressure goals can be carried out in adults with end-stage kidney disease and high blood pressure who receive peritoneal dialysis. The main questions it aims to answer are whether eligible patients can be recruited for the study. Researchers will compare two goals for the top blood pressure number (systolic blood pressure): below 120 mmHg versus below 140 mmHg.This pilot study will help plan a larger trial in the future. Participants will: * Be assigned by chance to one of the two blood pressure goals. * Have their blood pressure measured at clinic visits about every two weeks. * Work with their kidney doctor on recommended changes to fluid management, peritoneal dialysis treatment, or blood pressure medicines to reach their assigned goal. * Be part of the study for about four and a half months.

Recruiting
Has No Placebo

Satellite Healthcare - Daly City (+2 Sites)

Chi-yuan Hsu, MD, MS

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Barber and Pharmacist Coordination for High Blood Pressure

35 - 79
Male
Los Angeles, CA

The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged. The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men." It will build upon the foundational work of the original study and telemedicine pilot by evaluating the efficacy of a fully remote hypertension management program.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Christine Albert, MD, MPH

Image of Foothills Medical Center in Calgary, Canada.

Spinal Cord Stimulation for High Blood Pressure

18+
All Sexes
Calgary, Canada

High blood pressure, also called hypertension, raises the risk of heart disease, stroke, and kidney disease. Medications work well for many people, but some people still have blood pressure that stays too high, or they have side effects from their medications. Researchers are looking for treatments that do not involve taking more medication. Nerves help control blood pressure by changing how blood vessels tighten and how hard the heart pumps. Because of this, treatments that act on nerves may be able to lower blood pressure. Spinal cord stimulation is a treatment already used to manage long-term pain. It uses a small device, placed under the skin during a standard operation, that sends mild electrical signals to the spine. Laboratory studies suggest that stimulating the lower part of the mid-back may also lower blood pressure, but this has not been carefully studied in people who already use these devices. This study will look at whether changing the settings on a spinal cord stimulator affects blood pressure. About 11 adults who have high blood pressure and who already have a spinal cord stimulator for long-term pain. No new device will be placed, and no surgery or other invasive procedure will be done for this study. Participants attend a series of study visits. At each visit, trained staff record blood pressure and heart rate while the stimulator is turned on, turned off, and set to other settings that the person's care team has approved and that the person finds comfortable. There are rest breaks between each setting. Over successive visits, the study team works to identify the settings that best lower blood pressure. Participants can stop at any time, and their usual settings are restored at the end of each visit. The study will also look at whether this kind of testing is practical and comfortable for participants. The results will help researchers decide whether larger studies of spinal cord stimulation for blood pressure control are worth doing.

Waitlist Available
Has No Placebo

Foothills Medical Center

Aaron Phillips, PhD

Have you considered Midamor clinical trials?

We made a collection of clinical trials featuring Midamor, we think they might fit your search criteria.
Go to Trials
Image of Hillcrest Medical Center in Tulsa, United States.

Pedal Pump for Swelling in the Legs

18+
All Sexes
Tulsa, OK

Previous research on the osteopathic manual technique entitled "Pedal Pump" has shown health benefits, specifically increasing lymphatic flow, decreasing lower extremity edema, and decreasing serum lactic acid after maximal exercise. However, due to the limitation of human practitioners, research has been limited. The Pedal Pump is now a device which facilitates consistency in treatment and allows for increased sample size in research. This clinical trial studies the effects of 10 minutes of Pedal Pump treatment for hospitalized patients with lower extremity edema, almost the same as Pedal Pump Clinical Trial on Edema V1 that is underway; however, this study focuses primarily on the objective data gathered by trained Occupational Therapists who regularly measure lower extremities. Key Question for this second study: Is the Pedal Pump a feasible treatment for hospitalized patients? Secondary question: Does the Pedal Pump decrease lower extremity edema? This is a novel idea in its early stage of development, so Investigators anticipate product advancements, further testing with larger population sizes, and future publications.

Recruiting
Device

Hillcrest Medical Center

Hillcrest

Image of Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington in Arlington, United States.

Alcohol Abstinence for High Blood Pressure

26 - 49
All Sexes
Arlington, TX

The purpose of this study is to learn whether avoiding alcohol can improve heart and blood vessel health in adults who regularly drink alcohol and have high blood pressure. High blood pressure is a major risk factor for cardiovascular disease (CVD), including heart attack and stroke. In this randomized, controlled trial, men and women aged 26 to 49 years who regularly consume alcohol and have high blood pressure will be assigned by chance to either stop drinking alcohol or continue their usual drinking habits for 8 weeks. Researchers will compare changes in blood pressure and other cardiovascular disease risk factors between the two groups. The information gained from this study may help researchers and health care providers better understand the effects of alcohol consumption on cardiovascular health and whether alcohol abstinence can reduce heart disease risk, especially in adults with high blood pressure.

Recruiting
Has No Placebo

Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington

Image of Department of Family & Community Medicine; University of Alabama at Birmingham in Birmingham, United States.

Treatment for High Blood Pressure

18+
All Sexes
Birmingham, AL

The researchers will invite 30 patients in primary care who have high blood pressure to participate in this health program with a supportive partner of their choosing (these will be the "participant pairs"). Participant pairs will be invited to complete the Heart Care Pairs health program that will include up to six sessions each including 1) some education on a health habit like physical activity and heart healthy foods, 2) goal setting together, and 3) talk about healthy communication to support one another with heart healthy habits. The researchers will work with participants to address things that get in the way of coming for visits like offering transportation and offering telehealth visits. The researchers are seeing how this program works in real life so participants will be asked to complete as many sessions as they want to and can attend. The researchers will be interested in what participants think about the sessions, if they were satisfied with the visits, and if they would recommend the program to others in their community. The researchers will ask these questions in interviews with participants. The researchers will also ask up to 25 primary care workers about how they view the program as helpful to their work with patients with high blood pressure and whether they would refer more patients to the program in the future.

Waitlist Available
Has No Placebo

Department of Family & Community Medicine; University of Alabama at Birmingham

Image of London Health Sciences Centre (LHSC) in London, Canada.

BASIC-S Intervention for Cardiovascular Risk

18+
All Sexes
London, Canada

Vascular risk factors drive stroke, heart disease, and dementia, but translating lifestyle guidelines into routine clinical care remains challenging. To address this, we developed BASIC-S (Blood Pressure, Activity, Sleep, Interaction, Consumption, and Support), a framework targeting Blood pressure, Activity, Sleep, Interaction (socially), Consumption (nutrition), and Support using partner support and motivational interviewing. This individual-focused approach bypasses the logistical and financial barriers of complex clinical interventions by using sustained behavioral science to support gradual lifestyle changes. This study is a single-center, mixed-methods, cluster-randomized pilot trial evaluating the feasibility of the BASIC-S protocol in an occupational setting. A maximum of 60 households (120 participants) will be randomized 1:1 to either the BASIC-S intervention (motivational coaching, secure video check-ins, automated text messages, and a digital workbook) or standard care. Outcomes will assess feasibility, acceptability, and the validity of new tracking metrics to inform a future full-scale trial.

Waitlist Available
Has No Placebo

London Health Sciences Centre (LHSC)

Have you considered Midamor clinical trials?

We made a collection of clinical trials featuring Midamor, we think they might fit your search criteria.
Go to Trials
Image of NeuroFit Lab, Ivor Wynne Centre, McMaster University in Hamilton, Canada.

Isometric Handgrip Exercise for High Blood Pressure

65+
All Sexes
Hamilton, Canada

The goal of this clinical trial is to evaluate whether a short, supervised isometric handgrip exercise program is feasible and acceptable for older adults with elevated blood pressure or hypertension. It will also explore whether this type of exercise may improve blood pressure and cognitive function. The main questions it aims to answer are: * Is this handgrip exercise program practical and acceptable for older adults to participate in within a community exercise setting? * Does participation in the program lead to changes in blood pressure and cognitive function? Researchers will compare two handgrip devices to determine whether the method of delivering the exercise influences feasibility and outcomes. Participants will: * Be randomly assigned to use one of two handgrip devices. * Complete supervised exercise sessions twice per week for 4 weeks. * Perform brief handgrip contractions at a set intensity during each session. * Complete blood pressure and cognitive assessments before and after the program.

Recruiting
Has No Placebo

NeuroFit Lab, Ivor Wynne Centre, McMaster University (+1 Sites)

Jennifer Heisz, PhD

Image of Vanderbilt University Medical Center in Nashville, United States.

2-HOBA for Salt Sensitivity of Blood Pressure

18+
All Sexes
Nashville, TN

Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S. population in the hypertensive category. Excess dietary salt is a major risk factor for hypertension, with 50% of hypertensive individuals exhibiting salt-sensitivity of blood pressure (SSBP). SSBP is an independent predictor of cardiovascular events and death. While kidney mechanisms in salt-sensing have been extensively studied, emerging evidence suggests that immune cells can also sense sodium (Na+). This trial hypothesizes that myeloid cell-derived isolevuglandins (IsoLGs) drive endothelial dysfunction, perpetuating the salt-sensitive phenotype. Preliminary data indicate that targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks. This phase 2 clinical trial aims to investigate the role of 2-HOBA in modulating immune cell function within blood vessels in hypertensive patients. The study will explore the impact of immunity on salt sensitivity and assess 2-HOBA's potential to reduce endothelial dysfunction, improve immune cell activation, and alleviate SSBP.

Phase 2
Recruiting

Vanderbilt University Medical Center

Image of UPMC Magee Womens Hospital in Pittsburgh, United States.

Mobile Health Program for High Blood Pressure After Preeclampsia

18+
Female
Pittsburgh, PA

Strategies targeted to optimize hypertension (HTN) control for midlife women after hypertensive disorders of pregnancy (HDP) have not been studied, despite evidence of a critical need. This proposal targets the 10-20 years postpartum as a key time when women have subclinical cardiovascular (CV) sequelae of uncontrolled HTN and are primed for CV prevention interventions. Before proceeding with large-scale intervention trials of a home blood pressure monitoring (HBPM) and coaching intervention following HDP, further pilot testing is necessary. The overarching hypothesis of this proposal is that a new monitoring and treatment paradigm utilizing HBPM combined with a virtual coaching intervention would be better than standard of care for mid-life women with prior HDP who develop HTN. Women will be assigned in an unblinded manner to the intervention or standard of care control group.

Recruiting
Has No Placebo

UPMC Magee Womens Hospital

Malamo Countouris, MD, MS

Have you considered Midamor clinical trials?

We made a collection of clinical trials featuring Midamor, we think they might fit your search criteria.
Go to Trials